IFITM3 Antibody

Code CSB-PA002999
Size US$100
Order now
  • Western Blot analysis of HeLa cells using IFITM3 Polyclonal Antibody
  • Western Blot analysis of HELA cells using IFITM3 Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
1 8U antibody; Fragilis antibody; IFITM3 antibody; IFM3_HUMAN antibody; Interferon induced transmembrane protein 3 (1 8U) antibody; Interferon Induced Transmembrane Protein 3 antibody; Interferon inducible antibody; Interferon inducible protein 1 8U antibody; Interferon Inducible Protein 15 antibody; Interferon Inducible Protein Homolog antibody; Interferon-induced transmembrane protein 3 antibody; Interferon-inducible protein 1-8U antibody; IP15 antibody
Raised in
Species Reactivity
Synthesized peptide derived from the N-terminal region of Human IFITM3.
Immunogen Species
Homo sapiens (Human)
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
It differs from different batches. Please contact us to confirm it.
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Tested Applications
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IF 1:200-1:1000
ELISA 1:40000
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

IFN-induced antiviral protein which disrupts intracellular cholesterol homeostasis. Inhibits the entry of viruses to the host cell cytoplasm by preventing viral fusion with cholesterol depleted endosomes. May inactivate new enveloped viruses which buds out of the infected cell, by letting them go out with a cholesterol depleted membrane. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry. Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome. Exerts opposing activities on SARS-CoV-2, including amphipathicity-dependent restriction of virus at endosomes and amphipathicity-independent enhancement of infection at the plasma membrane.
Gene References into Functions
  1. Study showed that IFITM3 was upregulated in hepatocellular carcinoma (HCC) tissues and associated with HCC tumor size, tumor multifocal, and venous invasion. Furthermore, IFITM3 was identified as a new functional target gene of miR29a which expression was negatively correlated with that of IFITM3 in HCC tissues. These results indicated that IFITM3 play a critical role in the development and progression of HCC. PMID: 30272306
  2. a functional convergence between the mTOR pathway and IFITM3 proteins at endolysosomal membranes. PMID: 30301809
  3. We analyzed the population genetics of IFITM3 variants in the Portuguese general population (n = 200) and Central Africans (largely Angolan) (n = 148) as well as its association to influenza severity in Portuguese patients PMID: 28842783
  4. rs12252 C polymorphism of interferon-induced transmembrane protein 3 (IFITM3) is associated mild flu in Iranian population. Carriers of the rs12252 C allele (CT + CC genotypes) showed 5.92 folds increase in the risk of mild flu comparing to the T allele homozygotes. There is a significant positive association between rs12252 C allele heterozygote and mild flu but not in C allele homozygote group. PMID: 29121968
  5. A significant association between the IFITM3 rs12252 polymorphism and the risk of influenza in both the White and East Asian populations (meta-analysis). PMID: 29940276
  6. contrary to its role in enhancing DNA virus replication, LSD1 limits RNA virus replication by demethylating and activating IFITM3 which is a host restriction factor for many RNA viruses PMID: 29281729
  7. study predicts IFITM3 secondary structures and identifes a highly conserved, short amphipathic helix within a hydrophobic region of IFITM3 previously thought to be a transmembrane domain; show this helix and its amphipathicity are required for IFITM3-dependent inhibition of influenza virus, Zika virus vesicular stomatitis virus, Ebola virus and HIV infections PMID: 28835547
  8. frequencies of the CC genotype and the C allele in the IFITM3 polymorphism were higher in the Korean population than in the European populations but not in Chinese and Japanese populations; the rs12252 polymorphism of the IFITM3 gene did not significantly correlate with the disease severity of influenza A virus infection PMID: 28813716
  9. IFITM3 rs12252 CC genotype was associated with severity rather than susceptibility of IVI in Chinese population, and this strong effect was observed in all subtypes of seasonal influenza infection PMID: 28713779
  10. Identification of three distinct mutations that converted IFITM1 or IFITM3 from inhibitors to enhancers of MERS-CoV or SARS-CoV spike protein-mediated entry revealed key structural motifs or residues determining the biological activities of IFITM proteins. PMID: 29263263
  11. Results demonstrate that IFITM3 expression has a close relationship with prognosis in esophageal squamous cell carcinoma (ESCC) patients. Its overexpression may predict poor prognosis in stage IIA ESCC patients after Ivor Lewis esophagectomy. PMID: 28857475
  12. Study demonstrated, for the first time, that IFITM3 is expressed at a much higher level in lung cancer than in control tissues. Its knockdown could suppress lung cancer cell proliferation, invasion, and migration while inducing lung cancer cell cycle arrest and apoptosis. PMID: 28544512
  13. IFITM3 is upregulated in patient-derivedbrain tumor-propagating cells (BTPCs) upon irradiation but does not affect brain tumor formation or progression in vivo. PMID: 27835870
  14. These results indicate that IFITM3 protein can restrict alphavirus infection by inhibiting viral fusion with cellular membranes. PMID: 27219333
  15. The transcriptional regulation of IFITM1, 2 and 3 expression. PMID: 28511927
  16. IFITM1 and IFITM3 inhibit Zika virus infection early in the viral life cycle. PMID: 27268505
  17. We failed to confirm an association between the rs12252_C allele of IFITM3 and influenza susceptibility in 2 cohorts of children. PMID: 28531322
  18. homozygous IFITM3 CC and TLR3 CC genotypes showed significant independent associations with higher death risks in H7N9/H1N1pdm09 influenza in a large Chinese cohort PMID: 28510725
  19. We found evidence of a new association of rs34481144 with severe influenza in three cohorts characterized by different levels of influenza illness severity. rs34481144 is an expression quantitative trait locus (eQTL) for IFITM3, with the risk allele associated with lower mRNA expression. The risk allele was found to have decreased IRF3 binding and increased CTCF binding in promoter-binding assays. PMID: 28714988
  20. IFITM3 rs12252 variant was associated with respiratory infection hospitalization but not specifically in patients infected with Influenza A(H1N1)pdm09. PMID: 27351739
  21. findings show that the sensitivity of influenza A viruses to the IFN-induced antiviral state and IFITM2 and IFITM3 proteins depends on the pH value at which the viral HA undergoes a conformational transition and mediates membrane fusion PMID: 28356532
  22. cell-extrinsic and cell-intrinsic factors including IFITM3 have roles in regulating the efficiency and kinetics of virus entry and fusion with target cells PMID: 28341742
  23. Key features of the HIV-1 envelope protein that are associated with viral resistance to the IFITM3 protein. PMID: 28100616
  24. The study demonstrates that the human pulmonary endothelium possesses intrinsic immunity to human influenza viruses, in part due to the constitutive expression of IFITM3 proteins. PMID: 27707929
  25. The present study identified the transcripts, which were affected by the downregulation of endogenous IFITM3 and the pathways they were involved in. These findings may lead to an improved understanding of the biological functions of IFITM3. PMID: 27667301
  26. there is one transmembrane helix in the human IFITM3 with a possible role in virus entry PMID: 27046158
  27. These data do not suggest a role of rs12252-C in the development of severe influenza virus infection in the population. PMID: 27492307
  28. IFITM2 and IFITM3 specifically antagonize the HIV-1 envelope glycoprotein (Env), thereby inhibiting viral infection. PMID: 26387945
  29. we demonstrate that the E3 ubiquitin ligase NEDD4 ubiquitinates IFITM3 in cells and in vitro. PMID: 26263374
  30. propose that the IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation and demonstrate that the actions of the IFITM proteins are indeed virus and cell-type specific PMID: 26354436
  31. Our meta-analysis suggests a significant association between a minor IFITM3 allele (SNP rs12252-C) with severe influenza susceptibility, but not in mild influenza subjects PMID: 25942469
  32. A novel association between IFITM3 gene polymorphism and rapid disease progression is reported in an acute HIV-1-infected MSM cohort in China. PMID: 25784441
  33. This meta-analysis suggests that IFITM3 rs12252 T>C polymorphism is significantly associated with increased risk of severe influenza but not with the chance of initial virus infection. PMID: 25778715
  34. In virus-producing cells, IFITMs coalesce with forming virions and are incorporated into HIV-1 viral particles. PMID: 25422070
  35. Incorporation of IFITM1, IFITM2 and IFITM3 into HIV-1 virions impair viral fusion and spread. PMID: 25464829
  36. Authors suggest that IFITM3 adopts multiple membrane topologies involving at least one intramembrane domain in its antivirally active conformation. PMID: 25405885
  37. Taken together, these data suggested that IFITM3 is a potential therapeutic target for GC. PMID: 25270246
  38. Tyrosine 20 partially regulates the subcellular localization of IFITM3 but is not functionally essential for IFITM3-mediated H1N1 restriction. PMID: 25314048
  39. Host IFITM3,IFITM2 and IFITM1 facilitate morphogenesis of the human cytomegalovirus assembly. PMID: 25552713
  40. Exposure of A(H1N1)pdm09-infected epithelial cells to HIV-1 viral particles or its gp120 enhanced by 25% the IFITM3 content. resulting in a decrease in influenza replication. PMID: 24978204
  41. As an endocytic protein, IFITM3 first arrives at the plasma membrane before it is endocytosed and further traffics to the late endosomes where it acts to impede virus entry. PMID: 24521078
  42. IFITM3 may redirect IAV fusion to a non-productive pathway, perhaps by promoting fusion with intralumenal vesicles within multivesicular bodies/late endosomes. PMID: 24699674
  43. Authors found evidence of an association between rs12252 rare allele homozygotes and susceptibility to mild influenza (in patients attending primary care). PMID: 23997235
  44. The findings of this study provided new evidence that IFITM3 plays an important role in glioma cell growth and migration. PMID: 24370119
  45. The IFITM3 genotype is a primary driver of the observed differences in clinical outcome after H7N9 infection. PMID: 24367104
  46. The antiviral effector protein interferon-inducible transmembrane protein 3 (IFITM3) interacts with VAPA and prevents its association with OSBP. PMID: 23601107
  47. rs3888188, a functional promoter polymorphism of IFITM3, was identified to influence the risk for pediatric TB in Han Chinese population. PMID: 23874452
  48. Vesicular stomatitis virus and influenza A virus increased IFITM3-K88me1 levels by promoting the interaction between IFITM3 and SET7, suggesting that this pathway could be hijacked to support infection; conversely, IFN-alpha reduced IFITM3-K88me1 levels. PMID: 24129573
  49. IFITM3 protein was highly expressed in invasive breast cancer compared to normal tissues and was significantly associated with estrogen receptor and progesterone receptor status. PMID: 23624618
  50. Although their inhibitory activities were modest when compared to that of tetherin, IFITMs, but not tetherin, directly reduced the expression of HIV-1 proteins including Gag, Vif and Nef. PMID: 23376165

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type II membrane protein. Late endosome membrane; Single-pass type II membrane protein. Early endosome membrane; Single-pass type II membrane protein. Lysosome membrane; Single-pass type II membrane protein. Cytoplasm, perinuclear region.
Protein Families
CD225/Dispanin family
Database Links

HGNC: 5414

OMIM: 605579

KEGG: hsa:10410

STRING: 9606.ENSP00000382707

UniGene: Hs.374650

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To